Numerical modelling of photodynamic therapy by Baby Kumar, Vishnu
  
 
                
Numerical modelling of photodynamic therapy 
 
A dissertation submitted in partial fulfilment of the requirements for the degree of 
 
BACHELORS OF TECHNOLOGY 
IN 
BIOMEDICAL ENGINEERING 
By 
Vishnu B Kumar (107BM010) 
Under the mentorship of 
Professor Amitesh Kumar 
 
 
 
 
Department of Biotechnology and Medical Engineering 
National Institute of Technology 
Rourkela, 769008 (2010-2011) 
I 
 
 
National Institute of Technology 
Rourkela 
CERTIFICATE 
This is to certify that the thesis entitled “Numerical modelling of photodynamic therapy” by Mr 
Vishnu B Kumar submitted to the National Institute of Technology, Rourkela for the Degree of 
Bachelors of Technology in Biomedical Engineering, is a record of bona fide research work, 
carried out by him in the Department of Biotechnology and Medical Engineering under my 
supervision.  
I believe that the thesis fulfills part of the requirements for the award of Bachelors of 
Technology. To the best of my knowledge, the matter embodied in the thesis has not been 
submitted to any other University / Institute for the award of any Degree or Diploma. 
 
          Amitesh Kumar                                                                                          
Assistant Professor  
                                                         Department of Biotechnology and Biomedical Engineering  
Date                                 N.I.T Rourkela 
II 
 
ACKNOWLEDGEMENTS: 
 
This project is by far the most significant accomplishment in my life as a student of Biomedical 
Engineering at N.I.T Rourkela and I owe a major share of the credits to Prof. Amitesh Kumar, 
my deeply passionate project supervisor who showed relentless and immense faith in my calibre. 
It was he who guided me through, starting from the methodologies to the coding ending with the 
final simulation.  
This thanksgiving would be incomplete if I do not offer gratitude to all the faculty members of 
my department for their timely support and encouragement during this tenure. Let me also not 
forget my faithful friends and seniors for all their critical reviews and opportune motivation 
during the course of this project. 
And finally, I owe my utmost gratitude to God Almighty and my parents for all their prayers, and 
moulding me into the person I am. 
 
 
          Vishnu Baby Kumar 
 
 
 
III 
 
ABSTRACT: 
 
Photodynamic Therapy (PDT) is a new and minimally invasive cancer treatment modality based 
on the photo-activation of a light-sensitive drug „Photosensitiser‟ (PS). PS can be administered 
in various forms (e.g. as injection or ointment) and accumulates selectively in the target tumour 
tissue. This activated drug in turn generates singlet oxygen (
1
O2) in the malignant tissue and 
induces tissue necrosis or apoptosis. In this thesis, we have implemented a simulation model 
utilising the primary processes that the photosensitiser undergoes in the presence of irradiating 
light and molecular oxygen (
3
O2). We have used spectroscopic data of the commercially 
available and clinically significant photosensitiser „Photofrin®‟ (porfimer sodium, Axcan 
Pharma, Montreal, Canada, a heterogeneous mixture of porphyrins). This model encourages 
predictive statements to be made regarding the efficiency of photodynamic modalities at various 
initial conditions, including PS concentration and tissue oxygen concentration. 
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CHAPTER 1: INTRODUCTION 
(1.1) MOTIVE 
(a) CANCER: 
The focus of my thesis lies on a novel clinical treatment modality called the „Photodynamic 
Therapy’ which is based primarily on the interaction of light with human tissue and certain 
cancer-specific agents which can be exploited and utilised in our struggle against cancer.  
The W.H.O has described Cancer
1
 as the generic term given to a large group of diseases that can 
affect any part of the body. Other terms used are malignant tumours and neoplasms
1
. One 
defining feature of cancer is the rapid creation of abnormal cells that grow beyond their usual 
boundaries, and which can then invade adjoining parts of the body and spread to other organs. 
This process is referred to as metastasis
1
. Metastases are the major cause of death from cancer. 
Cancer spares no one – the young or old, the rich or poor, men, women or children; it is one of 
the leading causes of death in the world, particularly in developing countries and accounted for 
7.6 million deaths (around 13% of all deaths) in 2008
2
. Deaths from cancer worldwide are 
projected to continue to rise to over 11 million by the year 2030
1
. Many of these deaths can be 
avoided. Over 30% of all cancers can be prevented
1
. Others can be detected early, treated and 
cured.  
The utilisation of lasers in medicine
11
 has been overwhelming due to the possibility of varying its 
biological impact via the selection of wavelength, output power and, illumination time and mode. 
Conventionally, the thermal interaction of light with tissues is being exploited as a replacement 
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for the “cold knife”11. But this thesis considers a non-thermal regimen of utilising light within 
medicine referred to as the Photodynamic Therapy (PDT). 
In PDT, the tissue is sensitised to light by applying photosensitive agents called Photosensitisers 
(PS) administered topically or systemically. The therapeutic effect of PDT is attributed to the 
Reactive Oxygen Species (ROS)
17,22-25
 generated by the reaction of the excited photosensitiser 
molecules with oxygen following the non-ionising electromagnetic irradiation. In summary, a 
photochemical reaction is induced where the activated photosensitisers generate tissue damage 
through oxygen free radicals.  
(b) ADVANTAGES OF PDT OVER CONVENTIONAL MODALITIES
:15
 
Due to the selectivity of drug uptake by target cancer tissues and the control of light delivery, 
PDT has the potential of inducing effective cytotoxicity in the malignant tissue and limited 
damage to the surrounding healthy tissues. PDT has superior properties compared with 
conventional cancer therapies such as chemotherapy
3
 and radiotherapy
3
, these are;  
(1) it is selective15  
(2) it is non-invasive15, and  
(3) has fewer side effects15 
At the cellular and tissue levels, the free radicals can cause cellular or vascular damages and 
have immunological effects as mentioned above
15
. Over the past 30 years, PDT has been 
successfully applied for the treatment of a variety of types of cancers. Another commonly used 
term for PDT is “Photo Chemotherapy” (PCT).7,11 Although this designation encompasses a 
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wider definition, it is often preferred, more so since it emphasises on the actual mechanism 
involved i.e. the photochemistry behind PDT.  
(1.2) HISTORICAL BRIEFING ON THE PHOTODYNAMIC THERAPY: 
Light as a therapeutic agent
9
 has been in use for more than three thousand years. The Ancient 
Egyptian, Chinese and Indians civilisations used the combined action of natural plant extracts 
like chlorophylls with sunlight in attempts to cure disorders such as vitiligo, rickets, psoriasis, 
skin cancer and psychosis
9
.  
In 1898, the medical student Oscar Raab
11
 discovered by chance that the toxicity of the dye 
acridine to paramecia (alga) was dependent on the ambient light when performing the 
experiments, rather than to the concentration of the drug. This pioneering work was performed in 
the laboratories of Professor Herman von Tappeiner
11
 of Munich. Prof. Tappeiner continued the 
work and with Jodlbauer
11
 reported that the presence of oxygen was an indispensable factor. 
With this, he first coined the term „Photodynamic Therapy‟11 to describe the phenomenon of 
oxygen dependent photosensitisation.  
The discovery of PDT then paved way for the first medical application where Tappeiner together 
with dermatologist Jesoniek
11
 went on to perform PDT on humans, reported in 1903, with eosin 
as a photosensitiser.  
Thus, the application of photodynamic reactions to medicine gathered momentum but it was not 
until 1950s when the ability of a few tetrapyrrolic compounds called Porphyrins, to selectively 
accumulate in certain tissues i.e. in malignant tissues, was reported. Hausmann
11
 in Vienna 
performed the first studies on the biological effects of hematoporphyrin. In 1911, he reported on 
the combined effect of hematoporphyrin and light on a paramecium and red blood cells and 
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described skin reactions in mice exposed to light after hematoporphyrin administration. He, in 
particular described photosensitivity changes and some phototoxicity with intense light. The first 
report on the human photosensitisation by porphyrins was in 1913 by the German Friedrich 
Meyer-Betz
11
. Determined to find whether the same effects could be induced in humans as well 
as mice, he injected himself with 200 mg of hematoporphyrin and subsequently noticed 
prolonged pain and swelling in light-exposed areas. 
In a landmark paper, the concept that the combination of tumour localising and phototoxic 
properties of porphyrins could be exploited to produce an effective treatment for cancer was first 
proposed in 1972 in „The Lancet‟ by Diamond et al.15,26 from San Francisco. These authors 
validated the hypothesis that hematoporphyrin may serve as a selective photosensitising agent to 
destroy tumour cells exposed to light. They further concluded that PDT offered a new approach 
to the treatment modality of brain tumours and other neoplasms resistant to other existing forms 
of therapy. Refer Figure 1 for a historical overview of the photodynamic therapy. 
5 
 
 
Figure 1: Historical outlook of the photodynamic therapy, 1900 to present
5 
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(1.3) PHOTODYNAMIC THERAPY: THE PROCESS
 
The process of Photodynamic Therapy begins with the photo excitation of the photosensitiser 
(PS) drug that has been administered to the target tissue. Following this, is a cascade of processes 
that occur after a molecule of PS absorbs a photon having the appropriate energy (E=hν). The 
photochemical processes that take place during this irradiation process lead to the production of 
singlet oxygen that ultimately does the cancer cell damage.  
In the first step, the photosensitiser (PS) in its fundamental/ground singlet state (S0) absorbs light 
and is excited into its excited singlet state (S1). This process is reversible since the S1 state can 
revert back to the S0 state by a fluorescence emission
8
. Then, the excited state is converted by the 
Inter-System Crossing
17,19
 (ISC) process to the triplet state (T) of the photosensitiser. This 
triplet state can: 
(1) Either transfer its energy to the in-vivo dissolved molecular oxygen, which exits in the 
fundamental triplet state (
3
O2), generating singlet oxygen (
1
O2), or, 
(2) Revert to the fundamental S0 state via a phosphorescence
8
 process. According to the 
Frank-Condon Principle
15
, the time for an electronic transition (on the order of 10
-15
 s) 
is much shorter than that for a nuclear rearrangement. (on the order of 10
-13
 to 10
-14
 s) 
And so, this electronic transition occurs without causing any significant displacement of 
the nuclei. 
In the second step, we have the excited PS in its triplet form (T) which reacts with the molecular 
triplet oxygen (
3
O2) present in tissue to give singlet oxygen (
1
O2). Singlet oxygen is a highly 
reactive species of oxygen radicals having the innate ability to react spontaneously with cellular 
targets causing their apoptosis. The generated singlet oxygen may also undergo a 
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phosphorescence-mediated
8
 relaxation process back to its fundamental state. Ultimately, the 
generated singlet oxygen (
1
O2) also has the potential to react with the photosensitiser (PS) by a 
process called Photobleaching
19
, which hampers the overall singlet oxygen generation 
efficiency. 
The above reading suggests that in the course of Photodynamic Therapy, healthy cells are not 
necessarily spared, therefore it is imperative for the photosensitiser to accumulate selectively in 
the tumoural tissue to produce cancer cell necrosis (used interchangeably with „apoptosis‟) and 
to abate healthy tissue damage. As mentioned above, besides the reaction with cells, singlet 
oxygen can also react with the photosensitiser drug. This undesirable process photobleaching 
often leads to the irreversible inactivation of the photosensitiser hamepring the overall 
effectiveness of the photodynamic process. The efficiency of singlet oxygen generation depends 
on several factors, such as the molecular structure of the photosensitiser or its concentration and 
the in-vivo concentration of oxygen in the tissue of interest. 
In this thesis, we are interested in a Type II Photodynamic process
20
 which is the case when the 
excited PS reacts with molecular oxygen in tissue transforming it from its harmless triplet state 
to its highly potent singlet state; while a Type I Photodynamic process
20
 is where the same 
excited PS transfers its energy to a neighbouring atom or molecule thereby forming a free radical 
species. 
Summarising the reactions in step-wise fashion:
8,17 
 I - Irradiating target tissue with light post-application of the PS drug 
 II - PS transforms from ground singlet S0  state to excited singlet S1state 
 III - PS in S1 state converts to the triplet T state via ISC 
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 IV - PS in S1 state reverts to S0 state via fluorescence 
 V - PS in T state transfers energy to molecular oxygen, 3O2 state to 
1
O2 state 
 VI - PS in T state reverts to S0 state via phosphorescence 
 VII - Oxygen in singlet 1O2 state reverts to triplet 
3
O2 state via phosphorescence 
 VIII - Oxygen in singlet 1O2 state reacts with PS via photobleaching 
THREE KEY INGREDIENTS OF PHOTODYNAMIC THERAPY:  
(a) PHOTOSENSITISERS:
11,18 
The term photosensitiser encompasses a family of substances which are activated by light 
causing a biological effect. Historically, much of the work on photosensitisers revolved around 
the experiments on porphyrins. The name porphyrin comes from a Greek word for purple.
4
 One 
of the best-known porphyrins is heme
4
, the pigment found in human red blood cells; heme is a 
cofactor of the oxygen-carrier protein hemoglobin. Porphyrins are heterocyclic macrocycles (i.e. 
cyclic macromolecules) composed of four modified pyrrole subunits interconnected at their α 
carbon atoms via methine bridges (=CH-). They are aromatic. The simplest porphyrin is 
porphine
4
 (Figure 2), and in fact substituted porphines are called porphyrins.  
 
Figure 2: The structure of Porphine, the parent Porphyrin
4 
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In solutions, photosensitising compounds can have either negligible solubility in water or alcohol 
or maybe freely soluble in water and/or alcohol at the physiological pH (~7.365 of blood) 
As majority of the photosensitisers are large and possess a relatively complex molecular 
structure, they are usually administered by intravenous (IV) injection. An exception to this is d-
aminolevulinic acid (ALA),
11
 which is a precursor of the photosensitising compound 
Protoporphyrin IX (PpIX),
11
 wherein the target tumour tissues can themselves produce the PpIX 
compound for sensitisation following the administration of the precursor ALA. Protoporphyrin 
IX is, presently, one of the most utilised photosensitisers in clinical trials. 
Physico-Chemical properties of the photosensitiser are:
11,15 
(1) Chemical purity of the PS to avoid mutagenic effects.  
(2) Capability to localise11 specifically in malignant tissue. The fundamental requirement for 
optimum response to PDT is that a sufficient amount of the drug be localised in the target 
tissue. Initially, photosensitisers are taken up by most normal and hyperproliferating cells 
alike, but are retained longer in the tumour cells. Increased blood vessel permeability as 
well as poor lymphatic drainage in the malignant tissues contribute to the longer retention 
of the drug. 
(3) Short time interval between the administration of the drug (either systemic or topical) and 
its maximum accumulation in the host target tissue.  
(4) Rapid clearance18 from normal tissues. The fast clearance rate should ideally apply to all 
normal tissues, inclusive of  the liver, kidney and spleen as well. But at the same time, the 
clearance from the tumour tissues should be slower.  
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(5) Activation at wavelength with ideal tissue penetration. The marked feature of 
photosensitising agents is light absorption in a wavelength range where the ambient 
biological tissue is relatively transparent. The wavelength for optimal tissue penetration 
and that for maximal absorption should exhibit null disparity. 
(6) High quantum yield11 efficacies for the generation of the reactive singlet oxygen species 
i.e. a high yield of ROS per photon absorbed. 
(7) Lack of dark toxicity15 is another desirable feature of an ideal photosensitiser. A 
photosensitiser should exhibit a rather narrow absorption band, with little absorption at 
other wavelengths within the spectrum. This is to minimise the side effect of skin 
photosensitivity.
18
 
All these are very important for the overall efficiency of photosensitisation and thus the PDT. 
Other notable families of photosensitisers apart from Porphyrins are Chlorins, Purpurins, 
Pheophorbides, Napthalocyanines, and Porphycenes etc.
18 
DRAWBACKS OF PORPHYRIN-BASED PHOTOSENSITISERS:  
As stated above, most of the initial work on photosensitisation was performed utilising 
porphyrins and their relatives. However, scientists and researchers are in the quest for newer 
substances which best meet the requisites of the ideal photosensitiser. This is because Porphyrin-
based PS drugs suffer serious setbacks as a consequence of which, many different molecular 
structures are currently being investigated. But the whole field is in itself at its infancy. 
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Some of the deterrents in using porphyrin-based photosensitisers are:  
(1) Significant tissue penetration18 is achieved by light at 630 to 635 nm in the Infra-Red (IR) 
range, which however corresponds to the weakest absorption of most porphyrin drugs. So 
there is a trade-off between tissue penetration and degree of light absorption.  
(2) Cutaneous accumulation of porphyrin-based photosensitising drugs (i.e. both normal and 
tumour tissues absorb the drug at the same time) and their slow clearance from the skin 
lead to long-lasting skin photosensitivity,
9
 requiring the affected patient to avoid 
exposure to light from 4 to 6 weeks following a photosensitisation course.
18
 
 (b) LIGHT SOURCES:
11,18
 
Irradiation with light induces several processes when photons pass through the tissue; these are 
Absorption, Scattering, Transmittance and Fluorescence,
11
 all of which have been medically 
exploited. Photodynamic therapy as a treatment modality is governed by the accessibility of the 
target area to light application and facilitates the use of any light source with the appropriate 
wavelength spectrum. In the earlier days, photosensitisation was carried out with the help of 
conventional gas discharge lamps.  
Common examples of light sources : 
Metal halogen lamp, which emits 600 to 800 nm radiation at high power density, short-arc xenon 
lamp, tunable over a bandwidth between 400 and 1200 nm and the broad light beam emanating 
from incoherent lamps is useful for the treatment of large lesions. 
The introduction of lasers coupled with optical fibres heralded a new era in photosensitisation 
and expanded its applicability in medicine, promoting the endoscopic delivery of light to nearly 
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any site in the human body. In contrast to traditional incandescent lamps, lasers are equipped to 
provide us with the exact selection of wavelengths and the precise targeted application of light. 
FEATURES THAT MAKE LASERS UNIQUE: 
(1) Monochromatic11 i.e. containing one or a narrow range of wavelengths. This permits the 
light to match precisely an absorption band of the sensitiser in the region where its 
penetration in tissue is also at its largest and thus avoid thermally damaging the tissue 
with light that is not active in the photochemical reaction. 
(2) Coherent11 where the light waves emanating from a laser source are all in phase which 
makes lasers unique with respect to traditional lamps and permit the spot-on application 
of laser beam onto the target tissue. 
(3) Concentrated beam11 i.e. possessing a minimal angle of divergence facilitating easy 
focussing of lasers into optical fibres and thus favouring long distance near-lossless 
transmission. As a consequence was born various endoscopic techniques in which the 
laser-coupled optical fibres are transported into the body cavities or through the lumen of 
needles into tissue for interstitial illumination. Thus the laser has been considered the 
ideal choice as light source for PDT.  
When it comes to dye lasers,
11
 the apparent advantage is the possibility of being able to change 
the dye, and thereby also manipulate the emission wavelength within a certain region, making it 
possible to use the same laser in conjunction with various photosensitisers. 
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Common examples of clinically used lasers: 
The gold vapour laser (GVL)
18
 and the copper vapour laser-pumped dye laser (CVDL)
18
 (both 
being types of pulsed lasers), neodymium (Nd:YAG)
11
  laser (being a tunable solid-state laser) 
and gallium-arsenide (GaAlAs)
18
 (being a semi-conductor laser) are particularly useful for PDT. 
The conventionally used lasers like the GVC and CVDL are disadvantageous
18
 in that these 
lasers are bulky, expensive, relatively immobile, and require frequent maintenance checks.
18
 It 
has been acknowledged generally that regarding the source of light, much smaller and cheaper 
sources are to be investigated before PDT can become a future treatment modality for common 
use. 
This is where the development of semiconductor diode lasers like the Nd:YAG and GaAlAs 
lasers gains momentum as a novel approach to alleviate the aforesaid disadvantages. Besides 
having a convenient size, diode lasers are also reliable, economical and easy to use. 
A SMALL NOTE ON LAMPS AND LEDs:
11,18 
LAMPS:
11 
Filtered lamps constitute other possible light sources in PDT, which have already proved to be 
very useful. The advantages presented are a low price and a smaller form factor. In principle, 
lamps can only be used for superficial illumination. When filtered, the wavelength band achieved 
is quite broad unlike the narrow lasers. The emitted light outside the absorption band of the 
sensitiser was earlier presumed to have no other purpose than inducing hyperthermia
11
 of 
surrounding tissues. Later this hyperthermia was revealed to give an increased tumouricidal 
14 
 
effect. The Infra-Red (IR) band can be used for adding hyperthermia, but if undesired, can also 
be easily removed with the help of a simple water filter.  
LEDs:
11 
Light emitting diodes (LEDs) are also non-coherent light sources that can be employed for PDT. 
However given the infancy of the Photodynamic therapy and current technological progress, 
these alternate source have not yet been widely used. They emit in wavelength bands that are 
much broader than those from a laser and look promising in the future as they are predominantly 
simpler, cheaper and portable. 
A SMALL NOTE ON LIGHT DOSIMETRY:
11, 
The degree of penetration of light through tissue is dependent not just on the characteristics of 
the target tissue but also on the wavelength of the light. Moreover, the free passage of light is 
hindered by optical scattering within the tissue, the absorption by endogenous (in-vivo) 
chromophores, and the absorption of light by the sensitising drug itself. 
Using the present laser and low-powered LED technologies, the light needed to activate most 
photosensitisers cannot penetrate through more than one third of an inch (1 cm) of human tissue. 
Thus laser application of PDT is mostly confined to the treatment of tumours on or under the 
skin, or on the lining of some internal organs and consequently less effective in treatment of 
large tumours and metastasis. 
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(c) OXYGEN:
11,18
  
Investigations have purported the idea that the efficiency of the photosensitisation step of PDT is 
a direct consequence of the yield of 
1
O2 in the tumour environment and the yield of 
1
O2 in turn 
depends on the in-vivo concentration of oxygen in the tissue. Hypoxic cells are very tolerant to 
photosensitisation and the photodynamic reaction mechanism may itself consume oxygen at a 
rate conducive to induce a state of temporary hypoxia and stifle further photosensitisation 
effects. On the contrary, it has been reported, that hyperbaric oxygen can improve the effect of 
photosensitisation. 
Singlet oxygen 
1
O2 is a member of the general class of reactive species called Reactive Oxygen 
Species (ROS)
9
 that also comprises the free radicals: hydroxyl (OH
-
) and superoxide (O2
2-
), 
together with other reactive molecules such as hydrogen peroxide (H2O2) and hypochlorous acid 
(HClO). All these radical species are capable of oxidising biomolecules and induce cell death by 
apoptosis and/or necrosis mechanisms. We note that
 1
O2 free radicals are generated by 
photosensitisation of exogenous and/or endogenous photosensitisers and do not interconvert to 
other ROS whereas many ROS are the products of physiological processes and an inter-
conversion between them is feasible.  
The hallmark feature of 
1
O2  in the context of  PDT is its lifetime.
9
 The term lifetime of a sample 
refers to the time elapsed for a decline in its concentration by 1/e, or to ~37 % of the original 
concentration. Thus these 
1
O2  free radicals can exist in their excited states hardly for a fraction of 
time before reverting to their ground states by the loss of energy via a phosphorescence process 
as observed in PDT. 
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(1.4) FUTURE DIRECTIONS:
9,11
  
Now a century after Oscar Raab's ground-breaking work, the clinical propensity of PDT is 
finally being realised. PDT has been successfully employed in the treatment of many tumours, 
including skin cancer, oral cavity cancer, bronchial cancer, esophageal cancer, bladder cancer, 
head and neck tumours in addition to non-malignant diseases. The mechanism of action is 
continuously being defined along with the multitude of theoretical advantages over other cancer 
therapies.  
Presently, clinical trials on PDT emphasise its role in both the curative treatment of early 
tumours and the palliative
11
 (symptomatic) control of advanced cancer. However, PDT is not 
without its problems and before it becomes adopted as a clinical modality these have to be 
addressed. For instance, at the molecular level, the mechanisms for drug action, particularly the 
initial photochemical reactions leading to the generation of the ROS, have not been properly 
understood.
11
 Moreover, the efficiency of currently used PDT drugs is limited by the light 
penetration depth in tissue, since the absorption of these drugs lies in the visible light wavelength 
range (400 to 780 nm)
11
, where the attenuation of light in tissues is strong. So, despite there 
being a number of photosensitisers, right now, only a handful is approved for clinical use
15
. 
These are Photofrin
15
, Levulan
15
 (ALA) and Foscan
15
. The first health license was granted in 
Canada for Photofrin in 1993 for use in bladder cancer.
11
 Photofrin is now licensed in many 
countries and reigns supreme as the sensitiser with the most indications. Further trials with other 
sensitisers will no doubt lead to their licensing for clinical use, and this will propagate the vital 
role that PDT will have as the treatment of the future for both malignant and benign diseases.  
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CHAPTER 2: MATHEMATICAL MODELLING 
(2.1) OVERVIEW: THE MODELLING APPROACH 
7,8 
Our modelling framework is aimed at a clearer understanding of the fundamental processes 
involved to help expand the range of PDT and improve its clinical efficacy. The schematic of the 
energy level diagram
7
 (Figure3) illustrates various pathways of the PDT process and their 
corresponding rate constants.  
We have devised a numerical approach to quantitatively model a Type II photodynamic therapy 
(PDT) process in the time domain and thereby corroborate our results with the observations 
made by Hu et.al
7
  
In the course of modelling, we are considering the photochemical processes invoked by the 
irradiation of an aqueous solution of the photosensitiser drug with light; the resulting 
mathematical model is strongly based on the kinetic rate equations of the individual reactions. 
The relevant photoinduced processes have been represented in the Jablonski diagram
8,17
 
(Figure4) The PDT process starts with the absorption of photons by the PS in S0 state, having an 
adsorption cross-section, σpsa. Refer to Table 2 for a list of the various coefficients and 
parameters used. 
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Figure 3: Schematic Representation of the PDT Process
7 
(Refer to Table 1 for a description of the symbols used) 
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Figure 4: Simplified Jablonski diagram for PS-mediated singlet oxygen photogeneration
8 
Key: 
I: Absorption      II: Fluorescence            III: Inter System Crossing 
IV: Phosphoresence of PS    V: Phosphorescence of 
1
O2              VI: Photobleaching 
Degradation products 
from the PS 
1
O2 
S0 
3
O2 
1
O2 
3
O2 
T 
S1 
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The following are the six first-order differential rate equations
7
 that we come across in a Type II 
PDT process; 
Rate equations
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For a summary of the coefficients and parameters used in these equations and their 
corresponding values, refer to Table 2. 
The set of rate equations from (i) to (vi) have been solved using an implicit iterative method with 
the coding done in FORTRAN. 
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Table 1: Symbols used and their definitions
7 
Symbol Definition Symbol Definition 
τ1 Relaxation time of S1 to S0 ρ Photon density 
τ3 Relaxation time of T to S0 σpsa Absorption cross-section of 
S0 molecules 
τ0 Relaxation time of 
1
O2 to 
3
O2 [S0]i PS drug concentration in 
cells and tissues 48h after 
injection 
η10 Quantum yield of S1 to S0 step [S1]i Initial concentration of [S1] 
η13 Quantum yield of S1 to T step [T]i Initial concentration of [T] 
η30 Quantum yield of T to S0 [
3
O2] Initial concentration of [
3
O2] 
η0 Quantum yield of 
1
O2 to 
3
O2 [
1
O2] Initial concentration of [
1
O2] 
αs Efficiency factor for energy transfer 
from T to 
3
O2 
[R]i Initial concentration of 
intracellular molecular 
receptor for 
1
O2 
kpb Bimolecular photobleaching rate [C]i Scavenger concentration 
kcx Bimolecular cytotoxicity rate P Rate of O2 diffusion and 
perfusion 
ksc Bimolecular scavenging rate U Cell damage repair rate 
V Light speed in tissue = c/n = c/1.38   
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We have resorted to using an implicit versus an explicit solution method for this time-dependent 
problem due to the numerical stability of an implicit method, which being more complex to 
program and requiring more computational effort in each solution step permits large time-step 
sizes. In this thesis, for e.g. we have considered time points ranging from 10
-9
s to 10
3
s. 
Thus the time dependences of the photosensitiser (PS), oxygen (triplet and singlet states) and 
intracellular unoxidised receptor (R) concentrations were obtained and tandem decreases in the 
concentrations of the ground-state photosensitiser and receptor were observed. 
(2.2) THE IMPLICIT METHOD:
6 
Consider the differential equation, 
      
   ( ) 
  
  ( ( )) 
 
 
 
The implicit Euler method is represented by; 
 
 
                                                      (    )                        (vii)
 
 
 
That is, we are going to evaluate f at the current time (which is unknown), rather than previous 
time (which is known). Then the equation says “if you were at    , and took a step -
  (    )  you would end up at  .” This means if our differential equation represents a system 
that is reversible in time, this step makes sense. It is about finding a point      such that if we 
reverse time, we would end up at  . Unfortunately, we cannot in general solve for     directly 
instead we follow an iterative procedure. 
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We define    by    =      −   .Using this, we rewrite equation (vii) as 
 
                    ( (  )   
 (  )  ))                           (viii)
  
 
In many types of problems, the matrix represented by    will be sparse making solving process 
easier. For time-dependant problems involving stiff ODEs, the implicit method is the preferred 
choice. 
Implicit schemes are converged using iterations. These iterations usually involve solving a set of 
linear system(s) of equations that are either discrete forms of the original linear equations or 
linearised forms if the original equations are non-linear. 
This scheme is always numerically stable but usually more numerically intensive than the 
explicit method as it requires solving a system of numerical equations on each time step.  
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CHAPTER 3: RESULTS AND DISCUSSIONS 
Literature on PDT research was surveyed to select values of coefficients and parameters (refer 
Table 2 for the range of values used) and the set of rate equations in the time domain were 
solved. From that, we plotted graphs showing the time dependence of concentrations of 
photosensitiser, oxygen and unoxidised receptor and got to understand the dependence of 
photobleaching and cytotoxicity on drug dose and photon density. 
We plotted two graphs- Figure 5 , Figure 6  using the exact set of values taken by Hu et al.
 
and 
successfully validated our graphs with those obtained by them, thus ensuring that our approach 
was heading in the right direction. Next we plotted a set of graphs by varying only the 
photosensitiser concentration in its ground state [S0]- Figure 9, Figure 10 , and excited state [S1]- 
Figure 7, Figure 8; keeping all other parameters fixed. Detailed discussions have been entailed 
after the graphs. 
ASSUMPTIONS:
7 
(1) Differences in the optical parameters between tumour and normal tissues attributable to 
the physiological variations such as the extravasculature in the tumour and differential PS 
uptake. 
(2) Molecular parameters of PDT processes vary in different cells and their environments 
and, therefore, uncertainty does exist for selecting the parameter values. 
(3) Photobleaching or destruction of the PS can occur via two pathways : one by 
photochemical reaction of S0 with 
1
O2, and the other independent of oxygen . We limit 
our model on photobleaching to the former and described it by a reaction rate kpb in 
equation (v). 
26 
 
(4) Multiple types of intracellular receptors exist that react with 1O2 at different rates, hence 
kcx and [R] should be regarded as the averaged values over different species of receptors 
involved in the PDT process. 
(5) Refractive index n=1.38 for both tumour and normal tissue regions. The ranges of the 
tissue optical parameters were selected based on the values determined at light 
wavelength λ~630 nm. A total of 2.12x108 photons in a diverging beam of light have 
been tracked within the tissue phantom. Used various time steps between 0 ns and 
tmax=3000 s to achieve desired modelling. 
(6) Parameters set as [3O2]i=5.06x10
17
 (cm
-3
), [S0]i=5.00x10
13
 (cm
-3
),   =1.00x105 (cm-3), 
these concentrations were normalised by their initial values. (Figure 5) 
(7)  [S1], [T] and [
1
O2] were plotted using the normalised values of their corresponding 
maximum values [S1]m , [T]m and [
1
O2]m respectively. (Figure 6) 
Table 2: Values of coefficients and parameters in equations (i)-(vi)
7  
No: Symbol Definition Values Notes 
1. τ1 Relaxation time of S1 to S0 10 ns - 
2. τ3 Relaxation time of T to S0 30 or 300 µs - 
3. τ0 Relaxation time of 
1
O2 to 
3
O2 30 or 300 µs - 
4. η10 Quantum yield of S1 to S0 step 0.2 - 
5. η13 Quantum yield of S1 to T step 0.8 - 
6. η30 Quantum yield of T to S0 0.3 - 
7. η0 Quantum yield of 
1
O2 to 
3
O2 0.3 - 
8. αs Efficiency factor for energy 1x10
-17
 cm
3 
- 
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transfer from T to 
3
O2 
9. kpb Bimolecular photobleaching rate 2x10
-10
 cm
3
.s
-1 
kpb/kcx[R]~80 
M
-1
 
10. kcx Bimolecular cytotoxicity rate 2x10
-9
 cm
3
.s
-1
 - 
11. ksc Bimolecular scavenging rate 1x10
-9
 cm
3
.s
-1
 - 
12. V Light speed in tissue = c/n = c/1.38 2.17x10
10
 cm.s
-1
 - 
13. Ρ Photon density 5x104 to 5x107 
cm
-3 
- 
14. σpsa Absorption cross-section of S0 
molecules 
5x10
-13
 cm
2 
- 
15. [S0]i PS drug concentration in cells and 
tissues 48h after injection 
2x10
10
 to 2x10
14
 
cm
-3 
- 
16. [S1]i Initial concentration of [S1] 0 - 
17. [T]i Initial concentration of [T] 0 - 
18. [
3
O2] Initial concentration of [
3
O2] 4.98x10
17
 or 
5.06x10
17
 cm
-3
 
- 
19. [
1
O2] Initial concentration of [
1
O2] 0 - 
20. [R]i Initial concentration of intracellular 
molecular receptor for 
1
O2 
5x10
17
 cm
-3
 - 
21. [C]i Scavenger concentration 1x10
3
 cm
-3
 - 
22. P Rate of O2 diffusion and perfusion 1x10
12
 to 1x10
13 
cm
3
.s
-1
 
- 
23. U Cell damage repair rate 2.6x10
12
 cm
3
.s
-1
 - 
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Figure 5: [S0], [
3
O2], [R] versus time (validation graph 1) 
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Figure 6: [S1], [
1
O2], [T] versus time (validation graph 2) 
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Figure 7: [S1], [
1
O2], [T] versus time at [S1] ~10
13
 (cm
-3
) 
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Figure 8: [S1], [
1
O2], [T] versus time at [S1] ~10
14
 (cm
-3
) 
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Figure 9: [S0], [
3
O2], [R] versus time at [S0] ~10
14
 (cm
-3
) 
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Figure 10: [S0], [
3
O2], [R] versus time at [S0] ~10
13
 (cm
-3
) 
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These concentrations versus time graphs demonstrate two types of trends:  
(1) those for the ground-state molecules of PS, oxygen and unoxidised receptors are slow-
varying in response to the activation light, whereas  
(2) those for the excited molecules exhibit transient responses depending on the specific 
choice of relaxation times. 
The graphs show a decline in S0 concentration which is due to the conversion of PS into excited 
S1 and T states with time. Once a certain threshold limit is crossed, marked at time t=10s, S0 
concentration falls due to the process of photobleaching where the singlet O2 degrades the PS. At 
the same time, it may rise due to fluorescence of excited S1 back to S0 or phosphorescence of 
excited T to S0, hence the fluctuations in S0 concentration. 
The decline in 
3
O2 concentration is due to in-vivo molecular oxygen (
3
O2) being consumed and 
converted to ROS, here we note that there is a threshold oxygen concentration below which there 
is no cytotoxicity and PDT process in fact creates a pseudo-hypoxic condition which slows down 
PDT temporarily. Considering vascularisation of tissues, there is also a possibility of blood-
perfusion as well as gaseous diffusion of the oxygen which brings down its concentration though 
to a small extent. However phosphorescence of singlet oxygen to molecular oxygen can raise its 
concentration. 
The concentration of the unoxidised receptors R shows a fall after a limit since till that point, the 
cell‟s inherent repair mechanism U was able to nullify the cytotoxic effects of the ROS. Singlet 
oxygen has yield which is proportional to both the PS drug and molecular oxygen concentrations 
and when they exceed tolerance limits, the repair machinery fails and cytotoxic damage begins 
by oxidisation of various intracellular receptors at the PS binding sites. 
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CONCLUSIONS: 
One of the major hindrances in getting useful results from these simulations is the challenge of 
performing them such that the biological accuracy of the mathematical model is not 
compromised in the name of simplicity before we may perform the simulation. The ODEs found 
in these models are often nonlinear and stiff. The consequence of the stiffness is a trade-off 
between stability over accuracy.  
Results indicate that appropriate combinations of PS drug and light doses may be explored to 
achieve cytotoxicity in a tumour without significant photobleaching. Also we observed collateral 
tissue damage in addition to the killing of tumour cells at higher drug doses. 
To summarise, we have demonstrated the feasibility of modelling a Type II Photofrin-mediated 
PDT process by solving a set of rate equations to obtain the time dependence of the 
concentrations of PS, oxygen and intracellular unoxidised receptors. Each species followed 
differential decay rates. A threshold of oxygen was identified in our model under which no 
cytotoxicity occurred. With this approach, we elucidated the variations in drug dose at different 
concentrations of oxygen, which can be used to quantitatively investigate the photobleaching and 
cytotoxicity effect.  
Future research will undoubtedly be directed towards the development of better photosensitisers 
with increased tumour selectivity and fewer side effects, in particular the systemic toxicity and 
duration of photosensitivity. Simultaneously we need to focus on more efficient light delivery 
systems and better comprehension of the optical properties of tissues. And when all these issues 
have been resolved, photodynamic therapy will fully realise its potential as a major cancer 
treatment modality.  
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